Wednesday, 25 Apr 2018

You are here

Poor Prognosis of the MDA-5 Antibody in Dermatomyositis

Researchers from Hong Kong assessed the clinical associations seen with the anti-melanoma differentiation-associated gene 5 antibody (anti-MDA5 Ab) assay in consecutive patients with dermatomyositis (DM) and polymyositis (PM).

Twenty patients with either DM or PM who were followed in the Rheumatology Clinic of Kwong Wah Hospital, Hong Kong were recruited and underwent testing for the anti-MDA-5 antibody.

Anti-MDA5 Ab was found in 30% of patients with DM but not in DM patients. All patients with the antibody had clinically manifest amyopathic DM (CADM).  They were more likely to be male, younger and with shorter disease duration.

The MDA5 Ab profile identifies a subset of CADM with rapidly progressive interstitial lung disease (RP-ILD) and digital ulcers and was unaffected by treatment.

Another recent report from the American Journal of Medicine assayed 182 PM/DM patients for antiaminoacyl-tRNA synthetase (ARS) and MDA5 antibodies (Citation source https://buff.ly/2GC0EOG).

MDA-5 positive patients were more likely to have rapidly progressive ILD (RP-ILD) (55.8% vs. 25% versus 16.9%, P < 0.001) compared to those with ARS or without either antibody profile.

Whereas treatment responses and 5 year survival was poorest in the MDA5 group, the ARS patients had the best ILD improvement and survival (98% vs 50% in MDA5 group; P < 0.001).

MDA5-ILD patients are at risk for severe pulmonary manifestations, poor response to treatment and an unfavorable prognosis. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Lupus Subgroup Responds to Anti-CD22

The monoclonal antibody epratuzumab showed promise as a B-cell depleting agent in patients with concomitant systemic lupus erythematosus (SLE) and Sjogren's syndrome, a post-hoc analysis of two phase III trials found.

Wear Your Pajamas to Work for Lupus

I suspect that everyone in rheumatology has a special place in their hearts for lupus patients. Their disease is so cruel, and we have so little to offer them, but the young women (and some men) that I treat keep battling on. The longer I have cared for them, the more I wanted to do for them. Managing their illness alone did not seem like enough. 

SynBioSe: Combo Rituximab and Belimumab Succeeds in Severe Refractory Lupus

One of the driving pathogenic mechanisms in systemic lupus erythematosus (SLE) is the generation of immune complexes capable of inducing netosis (NET formation) and NET-derived DNA that may be an amplifying autoantigen and give rise to anti-nuclear autoantibodies (ANAs). 

Increased Comorbidity Burden in Lupus African Americans

Researchers from Vanderbilt University Medical Center used electronic health records (EHR) to perform a phenome-wide study comparing African American (AA-SLE) and Caucasian (C-SLE) with systemic lupus erythematosus (SLE) and found more comorbidities in AA-SLE, especially renal, cardiovascular, and infectious diseases.

The Consequences and Cure of Hepatitis C

I spent this past week seeing hepatitis C patients with our hepatologists, and being a rheumatologist, I was looking forward to seeing extra-hepatic manifestations of HCV that we read about in text-books - cryoglobulinemic vasculitis, sicca syndrome, porphyria cutanea tarda and many others. I suppose I should not be surprised that the week passed without seeing a single one of these.